|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03692 HANSOH PHARMA
Nominal 
36.720 -0.100 (-0.272%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 8,304,007 | 11.710% | 15,028,324 | 12,260,814 | 10,103,806 | 9,382,410 |
| Cost of Sales | (671,083) | 1.558% | (1,497,867) | (1,105,408) | (1,030,863) | (867,010) |
| Gross Profit | 7,632,924 | 12.700% | 13,530,457 | 11,155,406 | 9,072,943 | 8,515,400 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 5,009,342 | 35.823% | 6,550,581 | 5,085,182 | 3,766,155 | 2,948,428 | |
| Taxation | (751,401) | 35.822% | (995,120) | (713,357) | (488,652) | (364,681) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 4,257,941 | 35.823% | 5,555,461 | 4,371,825 | 3,277,503 | 2,583,747 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (581,886) | 13.926% | (1,077,663) | (988,570) | (838,326) | (250,943) |
| Depreciation & Amortisation | 196,771 | -0.255% | 393,018 | 401,349 | 366,381 | 344,602 |
| Directors' Emoluments | -- | -- | -- | 39,526 | 41,912 | 33,123 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 70.000 | 32.075% | 93.000 | 74.000 | 55.000 | 44.000 |
| DPS (cts) | 24.659 | -- | 38.147 | 31.056 | 19.311 | 8.711 |
| Dividend Payout Ratio (%) | 35.227% | -- | 41.018% | 41.968% | 35.110% | 19.797% |
| Cash flow per share ($) | -- | -- | 1.130 | 0.651 | 0.526 | 0.463 |
| NBV per share ($) | 6.228 | -- | 5.840 | 4.832 | 4.347 | 3.824 |
| Remarks: | Real time quote last updated: 28/08/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 4,257,941 |
| %Change | 35.823% |
| EPS / (LPS) | RMB 0.700 |
| NBV Per Share (¥) | RMB 6.228 |